Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT

Phase 4 Completed 300 enrolled University of Alabama at Birmingham GE Healthcare · collab

RandomizedParallel-groupTriple-blindDiagnostic

Summary

Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.

Timeline

Start: 2007-08
Primary completion: 2009-03
Completion: 2009-03

Outcome

Met primary endpoint

registry analysis (superiority or other test); Gastroview vs Omnipaque; p <0.001; difference in proportions 62; Binomial test of proportion NCT00478556 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Gastroview	Unknown	25 ml	Oral
Subject	Iohexol	Diagnostic / imaging agent	26 ml	Oral

Indications

No indication recorded.